University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 30 of 35
Pharmacogenomics in Autism Treatment
NCT00584701
HIV and Hepatitis Care Coordination in Methadone Treatment
NCT00608192
Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
NCT00716807
Expanded Prenatal Testing Options and Informed Choice
NCT00505596
Improving Cancer Pain Management Through Self-Care
NCT00708019
Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury
NCT00605527
Epilepsy Phenome/Genome Project
NCT00552045
Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
NCT00845013
Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts
NCT00464490
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
NCT00539617
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
NCT00545974
Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents
NCT00758771
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
NCT00619112
Telephone-Based Decision Support for Rural Patients
NCT01217333
Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis
NCT00683371
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
NCT00630890
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
NCT00678470
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
NCT00714129
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
NCT00525525
Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome
NCT00548782
Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia
NCT01140022
Parental Knowledge and Attitudes of Confidential Sexually Transmitted Infections (STI) Services for Teens
NCT01144871
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
NCT00751101
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
NCT00544804
Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)
NCT00514878
The Mental Activity and eXercise Trial for Seniors
NCT00522899
Randomized Controlled Trial of Bipolar Versus Ultrasonic Hemostasis Techniques in Thyroidectomy
NCT00524966
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
NCT00694889
Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
NCT00525135
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
NCT00627068
Measuring Effectiveness in Sleep Apnea Surgery
NCT00518128
Lucentis for Inflammatory Macular Edema Trial
NCT00498355
Sandostatin for Patients With Androgen Independent Prostate Cancer
NCT00510224
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
NCT00854373
Hypnosis for Smoking Relapse Prevention
NCT00770380
Tetralogy of Fallot Seed Grant
NCT00722826
Fotonovela for Type 2 Diabetes Mellitus
NCT00472095
Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast Magnetic Resonance Imaging (MRI)
NCT00722904
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
NCT00755313
Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions
NCT01011634
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
NCT01300793
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
NCT00515138
Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer
NCT00467220
Smoking Reduction and Cessation Interventions for Chinese
NCT00714532
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
NCT00488982
Interventions for Smoking Among Persons in Recovery
NCT00714896
Magnetic Mini-Mover Procedure to Treat Pectus Excavatum
NCT00466206
A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
NCT00221325
Study of the Mechanisms of Asthma
NCT00595153
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
NCT00698035
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.